Table 1 Patient Demographic and Clinical Characteristics
Characteristics | Patients, No. (%) | |||
|---|---|---|---|---|
Discovery cohort | Validation cohort | Plasma cohort | Overall | |
Total, n | N = 96 | N = 81 | N = 106 | N = 283 |
Age-year | ||||
Mean (SD) | 54.7 (11.0) | 54.2 (9.48) | 54.6 (10.1) | 54.5 (10.2) |
Median [Min, Max] | 56.0 [28.0, 81.0] | 53.0 [33.0, 79.0] | 55.0 [21.0, 83.0] | 55.0 [21.0, 83.0] |
Gender | ||||
Male | 46 (47.9) | 38 (46.9) | 65 (61.3) | 149 (52.7) |
Female | 50 (52.1) | 43 (53.1) | 41 (38.7) | 134 (47.3) |
Smoking_history | ||||
Never smoker | 75 (78.1) | 59 (72.8) | 68 (64.2) | 202 (71.4) |
Smoker | 21 (21.9) | 22 (27.2) | 38 (35.8) | 81 (28.6) |
Family history of lung cancer | ||||
No | 88 (91.7) | 77 (95.1) | 103 (97.2) | 268 (94.7) |
Yes | 8 (8.3) | 4 (4.9) | 3 (2.8) | 15 (5.3) |
Histopathology | ||||
Lung cancer | 80 (83.3) | 64 (79.0) | 26 (24.5) | 170 (60.1) |
Lung adenocarcinoma | 78 (81.3) | 63 (77.8) | 23 (21.7) | 164 (58.0) |
Squamous cell carcinoma | 1 (1.0) | 0 (0) | 3 (2.8) | 4 (1.4) |
Large cell carcinoma | 1 (1.0) | 1 (1.2) | 0 (0) | 2 (0.7) |
Benign disease | 16 (16.7) | 17 (21.0) | 30 (28.3) | 63 (22.3) |
Inflammation | 6 (6.3) | 5 (6.2) | 16 (15.1) | 27 (9.5) |
Pulmonary fibrosis | 3 (3.1) | 5 (6.2) | 5 (4.7) | 13 (4.6) |
Hamartoma | 0 (0) | 2 (2.5) | 4 (3.8) | 6 (2.1) |
Pulmonary sclerosing pneumocytoma | 1 (1.0) | 1 (1.2) | 4 (3.8) | 6 (2.1) |
Tuberculosis | 3 (3.1) | 1 (1.2) | 0 (0) | 4 (1.4) |
Fungal infection | 2 (2.1) | 2 (2.5) | 1 (0.9) | 5 (1.8) |
Atypical adenomatous hyperplasia | 1 (1.0) | 1 (1.2) | 0 (0) | 2 (0.7) |
Healthy control | 0 (0) | 0 (0) | 50 (47.2) | 50 (17.7) |
Stage | ||||
0 | 1 (1.3) | 0 (0) | 0 (0) | 1 (0.6) |
I | 76 (95.0) | 63 (98.4) | 10 (38.5) | 149 (87.6) |
II | 1 (1.3) | 1 (1.6) | 8 (30.8) | 10 (5.9) |
III | 2 (2.5) | 0 (0) | 4 (15.4) | 6 (3.5) |
IV | 0 (0) | 0 (0) | 4 (15.4) | 4 (2.4) |